美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

F/m Emerald Life Sciences Innovation ETF

45.33

0.0000

成交量：255

成交額：1.16萬

市值：1.28億

市盈率：- -

高：45.33

開：45.33

低：45.33

收：45.33

52周最高：48.78

52周最低：27.68

股本：281.70萬

流通股本：281.70萬

量比：0.18

換手率：0.01%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

Spyre Therapeutics旗下Spy003療法在第12周實現20%臨床緩解率及30%內鏡改善率

Guardant Health重磅里程碑：Guardant360® Cdx獲FDA批准，成為阿斯利康Ectamah™（Camizestrant）晚期乳腺癌伴隨診斷

Cogent Biosciences將向Hovione採購Bezuclastinib產品最低比例

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/LFSC"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":45.3275,"timestamp":1789405111615,"preClose":45.3275,"halted":0,"volume":255,"delay":0,"changeRate":0,"floatShares":2817035,"shares":2817035,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"09-14 13:13:34 EDT","open":45.3275,"high":45.3275,"low":45.3275,"amount":11626.44909,"amplitude":0,"askPrice":46.16,"askSize":200,"bidPrice":45.96,"bidSize":300,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":45.3275,"sharesOutstanding":2657035,"nav":45.4,"aum":125169389,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":46.02,"preClose":45.3275,"latestTime":"19:30 EDT","volume":10,"amount":452.9875,"timestamp":1789169406017,"change":0.6925,"changeRate":0.015278,"amplitude":0},"volumeRatio":0.177988},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2817035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.177988,"shares":2817035,"dividePrice":0,"high":45.3275,"amplitude":0,"preClose":45.3275,"low":45.3275,"week52Low":27.6794,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":45.3275,"committee":0.2,"eps":0,"divideRate":0,"volume":255,"delay":0,"ttmEps":0,"open":45.3275,"prevYearClose":36.6147,"prevWeekClose":45.3275,"prevMonthClose":45.79,"prevQuarterClose":45.2033,"fiveDayClose":46.1341,"twentyDayClose":47.0833,"sixtyDayClose":40.7444},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PBPH","LU2322448791.USD","IEHS","HELX","GNOM","LU1992135399.USD","TMED","BIB","FBT","XPH","PPH","BK4588","LU2272731865.HKD","RXL","PBE","LU1992135472.HKD","CANC","SYNB","MEDI","BME","BBP","BBH","XBIX","RSPH","IE00B5TLWC47.USD","IDNA","IBB","BIOY","PJP","IBRN","MRNX","LU2272731600.USD","IEIH","FTXH","AZNH","IYH","LFSC","LU2322448957.HKD","BK4585","PSCH","SBIO","MRNY","WDNA","LU2473716301.USD","LU2272731782.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121233294","title":"Spyre Therapeutics旗下Spy003療法在第12周實現20%臨床緩解率及30%內鏡改善率","url":"https://stock-news.laohu8.com/highlight/detail?id=1121233294","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121233294?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:03","pubTimestamp":1788868991,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics日前宣布，其研发管线中的关键候选药物Spy003在临床试验中交出了令人瞩目的阶段性答卷。数据显示，在接受治疗满12周的时间节点上，该疗法成功促成了20%的患者达到临床缓解状态，与此同时，30%的受试者在内镜检查中观察到了显著的病情改善迹象。这一成果不仅彰显了Spy003在疾病修饰层面的潜在威力，也为公司后续的注册性临床推进注入了强劲信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116354483","title":"Guardant Health重磅里程碑：Guardant360® Cdx獲FDA批准，成為阿斯利康Ectamah™（Camizestrant）晚期乳腺癌伴隨診斷","url":"https://stock-news.laohu8.com/highlight/detail?id=1116354483","media":"美股速递","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116354483?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 06:11","pubTimestamp":1788559873,"startTime":"0","endTime":"0","summary":"Guardant Health今日宣布，其Guardant360 Cdx液体活检产品已获得美国食品药品监督管理局的里程碑式批准，正式成为阿斯利康新型内分泌疗法Ectamah在晚期乳腺癌治疗中的伴随诊断工具。Guardant Health管理层在声明中表示，这一里程碑不仅是对公司技术实力的权威认可，更是对癌症患者个体化治疗承诺的有力践行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNOM","LU0109394709.USD","BK4196","GH","LFSC","GDOC","LU0320765992.SGD","GNMX","FFOX","PTH","BK4585","LU0889565916.HKD","EKG","BK4551","BK4535","HELX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107575074","title":"Cogent Biosciences將向Hovione採購Bezuclastinib產品最低比例","url":"https://stock-news.laohu8.com/highlight/detail?id=1107575074","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107575074?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 04:14","pubTimestamp":1788380059,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc. 已通过SEC文件披露，计划向Hovione采购Bezuclastinib产品的指定最低比例份额。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","BK4505","BK4139","LFSC","COGT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":10,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/LFSC\",params:#limit:6,delay:false,,,undefined,":[]}}